Sleep and Memory Consolidation in Adults With Attention Deficit Hyperactivity.

Attention Deficit Disorder With Hyperactivity Clinical Trial

— HYPNOS  

Official title:

Sleep and Memory Consolidation in Adults With Attention Deficit Hyperactivity.

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05876286
• Other study ID #: RC31/22/0488
• Status: Not yet recruiting
• Phase: N/A
• Start date: October 15, 2023
• Est. completion date: May 31, 2025

Study information

• Verified date: September 2023
• Source: University Hospital, Toulouse
• Contact: Mélanie PLANTON, PhD
• Phone: 05 61 14 59 62
• Email: planton.m[@]chu-toulouse.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Attention Deficit Disorder With Hyperactivity is associated with deficits in cognition and sleep. In healthy adults, memory consolidation processes are related to sleep spindle activity in the sleep electroencephalogram. This association is poorly characterized in adults with attention deficit hyperactivity. In this study, the purpose is to characterize sleep microarchitecture disorders through the analysis of different stage of sleep EEG activity during a polysomnographic examination in adult with mixed Attention Deficit Disorder With Hyperactivity presentation compared to healthy.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 36
• Est. completion date: May 31, 2025
• Est. primary completion date: May 31, 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria for all participants:

• Age from 18 to 45 years old

• Affiliated to the French health care system

Inclusion Criteria for attention deficit hyperactivity disorder patients:

• meeting Diagnostic and Statistical Manual (DSM)-5 criteria for mixed attention deficit hyperactivity disorder presentation without drug treatment for attention deficit hyperactivity disorder.

Exclusion Criteria for all participant:

• People not able to give consent, neurological disease (other than neurodevelopmental disorders; or any other serious disease (cancer, addiction, systemic disease)), untreated sleep apnea, major depression (Beck inventory > 15), untreated restless leg syndrome; pregnancy in progress or wish to become pregnant during the study or breastfeeding woman, drug treatment including benzodiazepine, neuroleptic or antidepressant before inclusion.

Exclusion Criteria for healthy volunteers:

• Subjective cognitive and/or sleep complaint.

Related Conditions & MeSH terms

• Attention Deficit Disorder With Hyperactivity
• Hyperkinesis

Intervention

Other:
• Neurological examinations
Neurological, neuropsychological, polysomnography examinations and multiple sleep latency test. The protocol is divided into three visits.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Toulouse

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Difference in signal power (db or µV 2) in the sigma frequency bands in N2 sleep	difference between 2 groups	1 day